MedTrace Logo

A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Healthy Males

NCT02306876 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2017-08-17

No results posted yet for this study

Summary

This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in healthy adult males.

Conditions

  • Healthy

Interventions

DRUG

PF-06412562 3mg BID

PF-06412562

DRUG

PF-06412562 15mg BID

PF-06412562

OTHER

Placebo

Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-19
Primary Completion
2016-06-14
Completion
2016-06-14
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02306876 on ClinicalTrials.gov